Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer

Molecular Cancer Therapeutics

Volumn 14, Issue 1, 2015, Pages 59-69

  Toren, Paul J ^a   Kim, Soojin ^a   Pham, Steven ^a   Mangalji, Azzra ^a   Adomat, Hans ^a   Guns, Emma S Tomlinson ^a   Zoubeidi, Amina ^a   Moore, William ^b,c   Gleave, Martin E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Viamet Pharmaceuticals   (United States)

^c Innocrin Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CYTOCHROME P450 17; CYTOCHROME P450 17A1; ENZALUTAMIDE; METRIBOLONE; ORTERONEL; PREGNENOLONE; STEROID 5ALPHA REDUCTASE 1; UNCLASSIFIED DRUG; VT 464; ABIRATERONE; ANDROSTANE DERIVATIVE; CYP17A1 PROTEIN, HUMAN; NAPHTHALENE DERIVATIVE; STEROID 17ALPHA MONOOXYGENASE; TRIAZOLE DERIVATIVE; VT-464;

ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; DRUG EFFECT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INTERFEROMETRY; LIGAND BINDING; LIQUID CHROMATOGRAPHY; LUCIFERASE ASSAY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROID ANALYSIS; TRANSACTIVATION ASSAY; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANDROSTENES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; NAPHTHALENES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STEROID 17-ALPHA-HYDROXYLASE; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922227588     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0521     Document Type: Article

References (31)

1. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, MillerK, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
3. Eichenberger T, Trachtenberg J. Effects of high-dose ketoconazole on patients who have androgen-independent prostatic cancer. Can J Surg 1989;32:349-52.
4. Collins CB, Rivera-Nieves J. Broadening the paradigm of mucosal dendritic cell-mediated induction of gut-homing on T cells. Gastroenterology 2014;146:854-5.
5. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-73.
6. Logothetis CJ, Basch E,Molina A, Fizazi K, North SA, Chi KN, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012;13:1210-7.
7. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309-22.
8. Montgomery B, Cheng HH, Drechsler J, Mostaghel EA. Glucocorticoids and prostate cancer treatment: friend or foe? Asian J Androl 2014;16:354-8.
9. Rafferty SW, Eisner JR, Moore WR, Schotzinger RJ, Hoekstra WJ. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. Bioorg Med Chem Lett 2014;24:2444-7.
10. Loriot Y, Zoubeidi A, Gleave ME. Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor. Urol Clin North Am 2012;39:517-31.
11. Yin L, Hu Q. CYP17 inhibitors-abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol 2014;11:32-42.
12. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24:1802-7.
13. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807-12.
14. Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, et al. A novel antiandrogen, compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Mol Cancer Ther 2013;12:567-76.
15. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007;67:10455-65.
16. Cliff DP, Jones RA, Burrows TL, Morgan PJ, Collins CE, Baur LA, et al. Volumes and bouts of sedentary behavior and physical activity: associations with cardiometabolic health in obese children. Obesity 2014;22:E112-8.
17. Santry HP, Pringle PL, Collins CE, Kiefe CI. A qualitative analysis of acute care surgery in the United States: it's more than just "a competent surgeon with a sharp knife and a willing attitude". Surgery 2014;155:809-25.
18. Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, et al. Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res 2012;18:3571-9.
19. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 2011;18:R175-82.
20. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-25.
21. Veldscholte J, Berrevoets CA, Ris-StalpersC, Kuiper GG, Jenster G, Trapman J, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41:665-9.
22. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:1541-50.
23. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 2005;48:2972-84.
24. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, et al. Androgen receptor inactivation contributes to antitumor efficacy of 17 {alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benz-imidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 2008;7:2348-57.
25. Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 2012;287:3777-87.
26. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012;72:2176-82.
27. Eisner J, Abbott D, Bird I, Rafferty S, WRM, RJ S. VT-464: A novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC). J Clin Oncol (Meeting Abstracts) 2012;30:e15167.
28. Eisner J, Abbott D, Bird I, Rafferty S, Moore W, Schotzinger R. Assessment of steroid hormones upstream of P450c17 (CYP17) in chemically castrate male rhesus monkeys following treatment with the CYP17 inhibitors VT-464 and abiraterone acetate (AA). Endocr Rev 2012;33:SAT-266.
29. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013;3:1020-9.
30. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 2014 May 29. [Epub ahead of print].
31. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 2013;3:1030-43.